CIK 0001936258 · Large accelerated filer
NewAmsterdam Pharma Co N.V.
Sign in to watch- Ticker
- NAMS
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- Netherlands
- Entity type
- operating
- Phone
- 35 206 2971
- Business address
- GOOIMEER 2-35, NARRDEN, Netherlands, 1411 DC
- Former names
- NewAmsterdam Pharma Co B.V.
Securities
- NAMS Ordinary Shares Nasdaq
- NAMSW Warrant Nasdaq
- 8-K Event Material agreement
- 4 Open-market buy Director bought 471 shares at $23.98 ($11,294)
- SCHEDULE 13G/A Stake Statement of Beneficial Ownership
- SCHEDULE 13D/A Stake Beneficial Ownership Report
- 8-K Event Results of operations
- 10-Q Report Quarterly Report
- 8-K Event Regulation FD disclosure · Other events
- 4 Planned sale Chief Operating Officer sold 98,612 shares at an average $21.26 ($2,096,655)
- 144 Insider Sale of Securities
- 8-K Event Executive or director change
- 4 Open-market buy Director bought 3,780 shares at an average $18.38 ($69,466)
- 4 Planned sale Chief Operating Officer sold 100,000 shares at an average $19.29 ($1,929,141)
- 4 Open-market buy Director bought 8,584 shares at $19.50 ($167,381)
- 144 Insider Sale of Securities
- 8-K Event Regulation FD disclosure
- 8-K Event Regulation FD disclosure · Other events
- 8-K Event Shareholder vote results
- 4 Grant or award See Remarks acquired 55,000 shares (grant or award)
- 4 Option exercise Director acquired 68 shares (option exercise)
- 3 Insider Initial Statement of Ownership
Page 6 of 21 · 415 filings